RecruitingNot ApplicableNCT05295368

Strategies for Kidney Outcomes Prevention and Evaluation - The SKOPE Study


Sponsor

Duke-NUS Graduate Medical School

Enrollment

896 participants

Start Date

Jul 21, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

Background: Chronic kidney disease (CKD) is a major public health threat associated with significant morbidity, high mortality, and reduced quality of life. However, empirical evidence is limited on strategies to enhance the effectiveness of care for CKD. The objective of the trial is to evaluate the effectiveness and cost-effectiveness of multicomponent primary care strategies in preserving kidney function among patients with CKD at primary care clinics in Singapore. Methods: A pragmatic, randomized controlled trial, in 4 socioeconomically diverse primary care clinics (polyclinics) in Singapore over 3 years. A total of 896 participants with CKD Stage 3 or worse aged ≥40 and \<80 years will be enrolled, with 224 from each polyclinic. Participants enrolled in each polyclinic will be randomly allocated to the intervention or usual care group in a 1:1 ratio. Intervention includes four components 1) training nurses as health coaches for motivational conversation and CKD specific lifestyle counseling on diet and exercise, using hybrid follow-up approach of in-person, telephone, and secure WhatsApp video meetings; 2)Training physicians in algorithm-based standardized management of CKD and hybrid care delivery;3) subsidy on sodium-glucose transport protein-2 inhibitors (SGLT-2i) for CKD; and 4) regular CKD case review meetings. Patients in the usual care arm will be treated by physicians and nurses who and are not trained in SKOPE treatment algorithms. Study outcomes: The primary outcome will be the eGFR total slope from randomization to final follow-up at 36 months. secondary effectiveness outcomes will be 1) Change in CVD risk score as measured by The Million Hearts Longitudinal ASCVD Risk Assessment score 2) Change in CKD quality of life measured by KDQOL-36TM


Eligibility

Min Age: 40 YearsMax Age: 79 Years

Plain Language Summary

Simplified for easier understanding

This study in Singapore aims to find the best strategies to slow the progression of chronic kidney disease (CKD) and prevent complications. It will compare different combinations of medications and monitoring approaches for patients with moderate to advanced CKD. **You may be eligible if...** - You are between 40 and 79 years old - You are a Singaporean citizen or permanent resident - You have been diagnosed with stage 3 or 4 chronic kidney disease (meaning your kidneys are working at 15–59% of normal capacity, confirmed by at least two tests 3 months apart) - You have been receiving care at a polyclinic in Singapore for at least 1 year **You may NOT be eligible if...** - You are already on dialysis or have had a kidney transplant - You are pregnant or breastfeeding - You have a terminal illness - You were hospitalized in the last 3 months - You have a history of leg/foot ulcers, severe mental illness, or are unable to give informed consent Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERMulticomponent intervention

Intervention includes four components 1) training nurses as health coaches for motivational conversation and CKD specific lifestyle counseling on diet and exercise, using hybrid follow-up approach of in-person, telephone, and secure video sessions; 2)Training physicians in algorithm-based standardized management of CKD and hybrid care delivery;3) subsidy on sodium-glucose transport protein-2 inhibitors (SGLT-2i) for CKD; and 4) regular CKD case review meetings.


Locations(1)

SingHealth Polyclinics

Singapore, Singapore

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05295368


Related Trials